- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, No Prior Chemotherapy
- Interventions
- Paclitaxel, Carboplatin, Bevacizumab
- Drug
- Lead sponsor
- David O'Malley
- Other
- Eligibility
- 18 Years to 90 Years · Female only
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2023
- U.S. locations
- 1
- States / cities
- Hilliard, Ohio
Sponsor Directory
Genentech, Inc. clinical trials
Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
1396
Shown on this page
12
Current sort
Recently updated
Sponsor scope
Genentech, Inc.
Additional filters apply within this sponsor.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 313–324 of 1,396 matching trials for sponsor Genentech, Inc..
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- CD20-Positive Lymphoid Malignancies, Chronic Lymphoid Leukemia, Hematological Malignancies, Non-Hodgkin's Lymphoma
- Interventions
- rituximab, ABT-263
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2025
- U.S. locations
- 4
- States / cities
- Tucson, Arizona • Stanford, California • Cleveland, Ohio + 1 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Ocrelizumab
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis
- Interventions
- Serum Neurofilament Light
- Diagnostic Test
- Lead sponsor
- Dent Neuroscience Research Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Amherst, New York
- Conditions
- Relapsed Refractory Multiple Myeloma
- Interventions
- Abemaciclib, dexamethasone, ixazomib, pomalidomide, Enasidenib, dexamethasone, ixazomib, pomalidomide, Cobimetinib, dexamethasone, ixazomib, pomalidomide, Erdafitinib, dexamethasone, ixazomib, pomalidomide, Venetoclax, dexamethasone, ixazomib, pomalidomide, Daratumumab, dexamethasone, ixazomib, pomalidomide, Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide, Selinexor, dexamethasone, ixazomib, pomalidomide
- Drug
- Lead sponsor
- Multiple Myeloma Research Consortium
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • Duarte, California • Atlanta, Georgia + 10 more
- Conditions
- Advanced Non-Clear Cell Kidney Cancer
- Interventions
- Bevacizumab, Atezolizumab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 4
- States / cities
- La Jolla, California • Boston, Massachusetts • Detroit, Michigan
- Conditions
- Hemophilia A With Inhibitor, Haemophilia A Without Inhibitor, Hemophilia B With Inhibitor, Haemophilia B Without Inhibitor
- Interventions
- Not listed
- Lead sponsor
- American Thrombosis and Hemostasis Network
- Network
- Eligibility
- Not listed
- Enrollment
- 395 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 29
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Diego, California + 23 more
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- Atezolizumab, Stereotactic Body Radiation Therapy
- Drug · Radiation
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Colorado Springs, Colorado • Highlands Ranch, Colorado
- Conditions
- Cutaneous Squamous Cell Carcinoma
- Interventions
- Atezolizumab
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Healthy Volunteers
- Interventions
- Astegolimab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 3
- States / cities
- Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin
- Conditions
- Hemophilia A
- Interventions
- Factor IX
- Drug
- Lead sponsor
- Tulane University
- Other
- Eligibility
- 12 Years to 120 Years · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 2
- States / cities
- Metairie, Louisiana • New Orleans, Louisiana
- Conditions
- Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma
- Interventions
- Atezolizumab Injection, Bevacizumab, Transarterial chemoembolization
- Drug · Combination Product
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
About this Genentech, Inc. sponsor directory page
- What this page lists
- U.S. ClinicalTrials.gov public records where Genentech, Inc. is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Genentech, Inc. trials.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.
Related: all sponsor pages, browse by condition, browse by drug or therapy, browse by U.S. city, or open the full search for Genentech, Inc..